National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Data and Safety Monitoring Guidelines
    Posted: 04/27/2000    Reviewed: 01/26/2005



Data and Safety Monitoring Guidelines






Background






Essential Elements






Special Circumstances






Appendix



Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
Related Pages
Data and Safety Monitoring Example Plans
Examples of NCI-approved Institutional Data and Safety Monitoring Plans, submitted by NCI-designated Cancer Centers.
Essential Elements of a Data Safety and Monitoring Plan for Clinical Trials Funded by the NCI

This document outlines the essential elements of an adequate plan for data and safety monitoring (DSM) of clinical trials. It is intended to assist investigators and institutions in the formulation of DSM plans for all phases of cancer clinical trials, in accordance with National Institutes of Health (NIH) requirements. We suggest that institutions sponsoring a significant number of clinical trials formulate institutional DSM plans that can be broadly applied to the individual trials in their portfolio. Investigators from institutions or organizations without institutional DSM policies may also find this document useful as a guide in fashioning suitable DSM plans for their individual trials.

To get an idea of what a final DSM plan might consist of, see Data and Safety Monitoring Example Plans.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov